We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

ERBA MANNHEIM

Erba Mannheim is an IVD solutions provider focused on improving health outcomes in developing nations. Originally fou... read more Featured Products: More products

Download Mobile App





Erba Mannheim Announces Availability of Validated Automated Protocols for ErbaLisa COVID-19 IgG and IgM ELISA Kits

By LabMedica International staff writers
Posted on 01 Sep 2020
Print article
Image: ErbaLisa COVID-19 IgM ELISA kit (Photo courtesy of Erba Mannheim)
Image: ErbaLisa COVID-19 IgM ELISA kit (Photo courtesy of Erba Mannheim)
Erba Mannheim (London, England) has announced availability of validated automated protocols for its range of ErbaLisa COVID-19 IgG and IgM ELISA kits in order to improve global availability of high-quality testing methods for SARS-CoV-2.

The ready-to-use ErbaLisa COVID-19 IgG and IgM ELISA kits allow for the qualitative and semi-quantitative detection of IgG/M antibodies to SARS-CoV-2 in human serum. Erba's solid phase assays use proven technology, and total incubation time is 50 minutes at room temperature with a simple one step serum dilution. ErbaLisa COVID-19 assays are built for superior performance and reliable interpretation of results. With full CE certification, the reliable and automation-friendly COVID-19 ELISA kits are now available through Erba's global distribution network, including in the US.

Optimized protocols for popular instruments manufactured by Dynex, Stratec, Awareness, and Delta Biologicals are now available, as well as for Erba's own analyzers including the ELAN 30s microstrip processor. Such protocols will help meet or exceed manual performance characteristics and start reporting clinical results faster and with more confidence.
"With more than one million ELISA COVID-19 tests already issued, we are confident this development will help labs adopt our high quality and high value tests more quickly," said Nikhil Vazirani, MD of Erba Mannheim.


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.